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between injury and ACLR.
Results: Days between ACL injury and surgery ranged from 9 to 67, with
a mean 31.0± 14.4 days. Greater days between ACL injury and ACLR was
associated with greater C2C:CPII ratios at the six-month follow-up
exam after ACLR (0.15± 0.02, r¼ 0.46, P¼ 0.03). All other associations
between biochemical markers and days between injury and ACLR were
weak (r ranged between -0.006 and -0.075, all p> 0.05).
Conclusions: Individuals who waited a greater number of days
between ACL injury and ACLR demonstrated higher C2C:CPII at the six-
month follow-up exam. Greater C2C:CPII may be influenced by aberrant
knee joint loading on an ACL deficient knee in the time in which
patients await ACLR. Conversely, it is possible that individuals with
worse injuries may wait longer to undergo ACLR, and they may have
greater C2C:CPII due to the initial severity of joint tissue injury. It is also
important to note that the 6-month assessment occurs at a later time
post-injury for those with longer time between injury and ACLR. Cau-
tion should be exercised in interpreting the results of this small pre-
liminary study. More research is needed to understand mechanisms
that may influence the association between days between ACL injury
and ACLR and increased C2C:CPII at 6 months after ACLR. It will be
important to determine if there is an optimal time frame to perform
ACLR that minimizes the risk of, or rate of progression to, future PTOA.
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ANALYSIS OF CLUSTERIN EXPRESSION CHANGES AS A BIOMARKER
OF OSTEOARTHRITIS
C.R. Fellows, C. Matta, H. Quasnichka, A. Mobasheri. Univ. of Surrey,
Guildford, United Kingdom
Purpose: The discovery and validation of arthritis-related biomarkers
and establishment of methodology for proteomic studies in osteo-
arthritis (OA) are needed. Proteomics strategies have identified many
proteins that may relate to pathological mechanisms of OA, however
targeted approaches are required to validate the roles of these proteins.
This study aimed to use mass spectrometry and western blotting to
identify peptides from several proteins in the secretome of chon-
drocytes, cartilage explants and osteochondral biopsies treated with
inflammatory cytokines over a 2-week period, to evaluate their
potential as biomarkers of OA progression.
Methods: Healthy cartilage was obtained from fetlock joints of skel-
etally mature horses, euthanized for unrelated veterinary reasons.
Cartilage explants were isolated using a 6 mm biopsy, with discs placed
intowells (3 discs per 1ml DMEMþ 1% Pen/Strep) before incubation for
24 hours (37 C, 5% CO2). After this equilibration period, the media was
removed and replaced with either fresh DMEM þ 1% Pen/Strep or
DMEM supplemented with 1% Pen/Strep containing TNFa and IL-1b
both at 10ng/ml. Explants were culture for 7e14 days with the cyto-
kines replaced every 4th day. For cell based assays chondrocytes were
isolated from tissue using 70U pronase for 1hr at 37 C and overnight
digestion at 37C using a 0.2% collagenase II solution. The cell suspen-
sion was filtered and washed before being seeded into culture flasks
and cultured until confluencewas reached (37C, 5% CO2). Once cultures
were established cells were split into two groups: healthy control
(DMEM supplemented with 1% Pen/Strep and 10% foetal calf serum) or
stimulated cells (DMEM as above plus TNFa and IL-1b both at 10ng/ml).
Chondroyctes were cytokine-stimulated for up to one week. Cells were
used in experiments up to the 2nd passage.
Results: Mass spectrometry data showed that peptides representative
of clusterin were found to decrease following 7 days of inflammatory
stimulation. Western blotting of secreted proteins in media of cartilage
explants or chondrocyte showed that clusterin expression was reduced
following 7 days of cytokine treatment. Catabolic matrix metal-
loproteinase enzymes MMP1, MMP3 and MMP13, as well the matrix
component cartilage oligomeric protein (COMP) were all found to have
an increased abundance in the media of the cytokine treated samples.
This data was supported by qPCR for clusterin gene expression which
showed initially mRNA levels increased 3 day after inflammatory
stimulation but expression was lost after 7 days. Western blotting of
media from the osteochondral biopsies showed an increase in clusterin
expression after 7 days of inflammatory stimulation however clusterin
protein expression could not be detected after 14 days of treatment,
indicating a delayed response compared to cartilage tissue alone.
Conclusions: The equine chondrocytes, cartilage explant and osteo-
chondral biopsy models exhibited highest clusterin secretion inuntreated cultures. IL-1b and TNFa treatment caused a reduction in
clusterin secretion. Clusterin acts as a chaperone to aid protein refolding
in situations of stress and is constitutively secreted by mammalian cells.
IL-1b and TNFa appear to interrupt clusterin secretion and therefore the
protection it may offer healthy functioning cells. Previous studies have
reported variable data, with some studies indicating a decrease in clus-
terin in OA, while others indicate an increase in clusterin expression. Our
results suggest the clusterin increases immediately after inflammatory
stimulation but is lost after prolonged exposure. Therefore, levels of
secreted clusterin may be a candidate biomarker for OA progression.
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URINE METABOLOMICS USING LIQUID CHROMATOGRAPHY
QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY INDICATES
COMMON MARKERS OF DISEASE IN ALKAPTONURIA AND
IDIOPATHIC OSTEOARTHRITIS IN HUMAN
B. Norman y, A. Davison z, P. Wilson y, G. Ross x, A. Milan z, N. Roberts z,
L. Ranganath z, J. Gallagher y. y Inst. of Ageing & Chronic Disease, Univ. of
Liverpool, Liverpool, United Kingdom; z Liverpool Clinical Lab., Royal
Liverpool & Broadgreen Univ. Hosp. Trust, Liverpool, United Kingdom;
xAgilent Technologies UK Ltd, Cheadle, United Kingdom
Purpose: Osteoarthritis (OA) is associated with destruction of cartilage
and is widespread in Alkaptonuria (AKU), a serious genetioarthritic
disease caused by a deficient enzyme, homogentisate 1,2-dioxygenase
(HGD) and with morbidity caused by increased levels of homogentisic
acid (2,5-dihydroxyphenylacetic acid; HGA) and resultant pigmentation,
particularly of cartilagenous tissue. AKU is a severe, ultra-rare osteo-
arthropathy but there is considerable interest in using it as a model
system to study pathological changes in common idiopathic OA (iOA). In
support of this, some of the striking pathological features characteristic
of AKU-associated cartilage destruction are observed at lower frequency
in iOA. These include thinning of the subchondral plate, loss of collagen
fibril integrity, high-density mineralised protrusions and aberrant bone
remodelling. It was predicted that shared underlying biochemical pro-
cesses underlie these common features of disease, and that these are
detectable in biological matrices such as urine and serum. A non-tar-
geted metabolomic profiling experiment using Liquid Chromatography
Quadrupole Time-of-Flight Mass Spectrometry (LC-QTOF-MS) inves-
tigated this hypothesis using urine from human AKU and iOA patients.
Spectra were compared with those from healthy controls.
Methods: Human urine samples were from AKU patients (n¼ 15), iOA
patients (n¼ 7) and age-matched healthy volunteers (n¼ 30). All
samples were analysed using reverse phase Ultra-High Performance
Liquid Chromatography (UHPLC) on an Agilent 1290 Infinity UHPLC
system coupled to an Agilent 6550 Quadrupole Time-of-Flight mass
spectrometer in positive and negative polarity Electrospray Ionisation
(ESI).The data were processed using a feature finding algorithm
(Molecular Feature Extractor). This interrogates the 3-D data space
extracting chromatographic peaks representing compounds and the
associated MS spectra including isotopes, adducts and multimers. The
extraction and data reviewwere performed usingMass Hunter Profinder
software for alignment and elimination of false positives/negatives. The
resulting ‘found’ entities were compared across the three sample sets
using Mass Profiler Professional.
Results: Various quality control checks indicated that the LC-MS oper-
atingparameters and featurefinding across sampleswere reproducible. A
total of 109 and275 andmetabolic entities passed quality controlfiltering
and were aligned across all sample groups in positive and negative ESI
respectively. Interrogation of the variance across all datasets using Prin-
cipal Components Analysis (PCA) showed clear separation between the
urine metabolic profiles of AKU, iOA and controls. However, a number of
entities were identified as up or down regulated in both AKU and iOA
comparedwith controls indicating that there are commonmechanismsof
disease in these two conditions . Inpositive ESI,17 and 4 entitieswere up-
and down-regulated respectively in AKU and iOA compared with con-
trols. In negative ESI, 38 and 9 entities were up- and down-regulated
respectively in AKU and iOA compared with controls. These metabolic
entities span a relatively broad range in mass (100-800 Daltons) and
retention time, suggesting diverse chemical identities. Putative identities
for these entities can be derived based on accurate mass and retention
time using web-based databases (e.g. METLIN), supporting further
investigation using a more-targeted metabolomics approach.
Conclusions: Analysis of urine samples through metabolomic profiling
indicated presence of a number of entities that were up or down-
